



(51) International Patent Classification:

A61K 31/522 (2006.01) A61P 35/00 (2006.01)
A61P 31/12 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2019/033896

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

24 May 2019 (24.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/676,433 25 May 2018 (25.05.2018) US

(71) Applicant: PRIMMUNE THERAPEUTICS, INC.

[US/US]; Jlabs San Diego, 3210 Merryfield Row, San Diego, CA 92121 (US).


(72) Inventors: WEBBER, Stephen, E.; 3531 Millikin Avenue, San Diego, CA 92122 (US). APPLEMAN, James, Richard; 4818 Longford St., San Diego, CA 92117 (US).

(74) Agent: PINO, Mark, J. et al.; Mintz Levin Cohn Ferris Glosky and Popeo, PC, 701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TLR7 AGONISTS



(I)

(57) Abstract: The present invention relates to TLR7 agonists according to Formula (I) and their use in the treatment of diseases such as cancer and infectious disease.

